Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: Results from a randomized, multicenter, open-label, phase i study

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 387-395

  Wolin, Edward M ^a   Hu, Ke ^b   Hughes, Gareth ^b   Bouillaud, Emmanuel ^b   Giannone, Vanessa ^b   Resendiz, Karina Hermosillo ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Gastroenteropancreatic neuroendocrine tumor (GEP NET); Pasireotide (SOM230); Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

ANGIOPEPTIN; GLUCOSE; OCTREOTIDE; PASIREOTIDE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP INTRAGLUTEAL INJECTION; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLUSHING; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; LIVER METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUROENDOCRINE TUMOR; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; SUSTAINED DRUG RELEASE;

BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DEFECATION; DELAYED-ACTION PREPARATIONS; DIARRHEA; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; NEUROENDOCRINE TUMORS; SOMATOSTATIN;

EID: 84880918004     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2202-1     Document Type: Article

References (28)

1. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934-959 (Pubitemid 36173145)
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
3. Pinchot SN, Holen K, Sippel RS, Chen H (2008) Carcinoid tumors. Oncologist 13:1255-1269
4. Patel YC, Srikant CB (1997) Somatostatin receptors. Trends Endocrinol Metab 8:398-405 (Pubitemid 28160244)
5. Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H (1998) Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77:632-637 (Pubitemid 28059472)
6. Strosberg JR, Nasir A, Hodul P, Kvols L (2008) Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2:113-125
7. De Herder WW, Hofland LJ, Van der Lely AJ, Lamberts SW (2003) Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10:451-458 (Pubitemid 38094881)
8. Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31:169-188
9. Harris AG (1994) Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 35(Suppl):S1-S4
10. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140 (Pubitemid 13243115)
11. Anthony L, Freda PU (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 25:2989-2999
12. Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74 (Pubitemid 351680237)
13. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781-2789
14. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 362:1846-1848
15. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
16. Kvols L, Oberg K, O'Dorisio T, Mohideen P, De Herder W, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B (2012) Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 19:657-666
17. Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K (2012) Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol 52:1017-1027
18. Chan JA, Ryan DP, Zhu AX, Abrams A, Wolpin BM, Malinowski P, Regan E, Fuchs CS, Kulke M (2012) Phase I study of pasireotide (SOM230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer 19:615-623
19. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lübbert H (1994) Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 733:138-146
20. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600-606 (Pubitemid 29075248)
21. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW (2005) Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 28:36-42
22. Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47-50 (Pubitemid 39382369)
23. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716 (Pubitemid 34552506)
24. Prasad V, Fetscher S, Baum RP (2007) Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine's view. J Pharm Pharmaceut Sci 10:321s-337s (Pubitemid 47249277)
25. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508
26. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Hrader J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656-4663
27. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005-2012
28. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC (2011) Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934-943